drugset / Trial / NCT07370818

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

NCT07370818

Phase 2 Not yet recruiting 81 enrolled Onconic Therapeutics Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients

Timeline

Start
2026-02-27
Primary completion
2029-12-31
Completion
2031-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody
Subject Nesuparib Small molecule

Indications